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Highlights • CD53 is essential for lymph node cellularity as there is a paucity of T and particularly 
B lymphocytes in Cd53-/- lymph nodes  • CD53 is essential for lymphocyte homing to lymph nodes and the expression of the 
adhesion molecule L-selectin  • CD53 restrains both ADAM-17 dependent and independent L-selectin shedding • The importance of CD53 and lymphocyte recirculation to immunity is illustrated by 
the diminished immune responses to antigens delivered to lymph nodes in Cd53-/- 
mice 
 
Etoc (40 word limit) 
 
The function of the leukocyte-specific tetraspanin CD53 was unknown. Here, by analysing 
CD53-deficient mice and human lymphocytes, we demonstrate that CD53 is critical for 
lymphocyte recirculation as it stabilises the cell surface expression of the lymph node homing 
receptor L-selectin. 
 
Abstract (150 word limit) 
 
Tetraspanins regulate key processes in immune cells; however, the function of the leukocyte-
restricted tetraspanin, CD53 has remained unknown. Here we show that CD53 is essential for 
lymphocyte recirculation. Lymph nodes of Cd53-/- mice were smaller than wild-type mice due 
to a marked reduction in B cells and a 50% decrease in T cells. This reduced cellularity 
reflected an inability of Cd53-/- B and T cells to efficiently home to lymph nodes, due to the 
near absence of L-selectin from Cd53-/- B cells and reduced stability of L-selectin on Cd53-/- T 
cells. Further analyses, including on human lymphocytes, showed that CD53 inhibits L-selectin 
shedding via both ADAM17-dependent and -independent mechanisms. The disruption in 
lymphocyte recirculation in Cd53-/- mice led to impaired immune responses dependent on 
antigen delivery to lymph nodes. Together these findings demonstrate a previously 
unrecognized essential role for CD53 in lymphocyte trafficking and immune responses.  
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Introduction 
 
To initiate an adaptive immune response, antigen selects and clonally expands rare antigen-
specific lymphocytes from a vast repertoire of specificities. The frequency of antigen-specific 
lymphocytes within the naïve repertoire is minute, estimated in mice to be as low as 15-20 cells 
per animal (Moon et al., 2007; Obar et al., 2008), while in humans, frequencies can range from 
0.6 to 6 cells per million cells (Alanio et al., 2010; Chu et al., 2009). It is therefore not surprising 
that the immune system has evolved strategies to maximise the chances of a successful 
encounter between antigen and rare antigen-specific lymphocytes. To this end, naïve 
lymphocytes constantly patrol throughout the body, recirculating through the peripheral lymph 
nodes via interactions within specialised high endothelial venules (HEVs). Then, upon 
dwelling in the lymph nodes for 12-24 hours, they return to the vasculature via the efferent 
lymphatics, enabling them to visit further peripheral lymph nodes (Gowans, 1959; Smith and 
Ford, 1983; Springer, 1994). 
 
Many of the molecular interactions that govern the egress of naïve lymphocytes at HEVs are 
well understood, and the key molecule responsible for lymph node homing is the membrane 
receptor L-selectin (Grailer et al., 2009; Springer, 1994). L-selectin mediates carbohydrate-
based interactions with its HEV-expressed ligands termed peripheral node addressin (PNAd), 
thus initiating the tethering and rolling of naïve lymphocytes within HEVs (Streeter et al., 
1988) and ultimately leading to stable adhesion and the transmigration of naïve lymphocytes 
into the lymph nodes (Ivetic, 2013). Essential to the control of lymphocyte trafficking is the 
tight regulation of L-selectin expression. Upon activation, L-selectin is rapidly cleaved from 
the lymphocyte surface predominantly by the metalloprotease ADAM17. This loss of L-
selectin is thought to prevent effector cells from homing to peripheral lymph nodes thereby 
indirectly promoting their trafficking to peripheral sites, although this has not yet been shown 
experimentally (von Andrian and Mackay, 2000). The molecules that regulate L-selectin 
shedding are still under investigation and include calmodulin, ERM proteins and protein kinase 
C (Ivetic, 2013).  
 
Tetraspanins are four-transmembrane proteins that play a key role in the molecular organisation 
of cellular membranes. There are 34 tetraspanins encoded by the human genome, and these 
molecules interact with and organise their partner proteins into signal-transducing 
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microdomains (Rubinstein et al., 2013). In immune cells, the tetraspanin molecular partners 
include integrins, immunoreceptors and signalling molecules; thus, tetraspanins control key 
processes such as immune cell adhesion, migration and activation (Jones et al., 2011; Yeung 
et al., 2018). The functions of many of the immune cell-expressed tetraspanins are now well 
documented. For example, in B cells, the tetraspanin CD81 promotes adhesion strengthening 
of 41 integrin (Feigelson et al., 2003) and additionally serves as a key component of the 
CD19/CD21 co-receptor complex that lowers the threshold of B cell signalling (van Zelm et 
al., 2010). In dendritic cells, CD81 (Quast et al., 2011) and the tetraspanins CD37 and CD82 
(Gartlan et al., 2013; Jones et al., 2016) regulate the cytoskeletal rearrangements that drive 
migration. CD37 is also required for integrin function, both in neutrophils where it is required 
for inflammation-associated recruitment (Wee et al., 2015), and in B cells where it is essential 
for transducing survival signals during the germinal centre reaction (van Spriel et al., 2012).  
 
By contrast, the function of the pan-leukocyte marker CD53 remains obscure.  Despite being 
one of the first discovered members of the tetraspanin superfamily (Amiot, 1990), CD53 has 
not been robustly examined, with a range of in vitro studies weakly suggesting a variety of 
roles. Crosslinking CD53 at the cell surface can lead to leukocyte activation (Bell et al., 1992; 
Bosca and Lazo, 1994; Cao et al., 1997; Lagaudriere-Gesbert et al., 1997; Lazo et al., 1997), a 
result perhaps explained by more recent sophisticated analyses that demonstrate a role for 
CD53 in PKC signalling (Zuidscherwoude et al., 2017). Transfection and expression studies 
have suggested a role in the regulation of apoptosis (Kim et al., 2004; Yunta and Lazo, 2003) 
and T cell development (Puls et al., 2002), while genetic and phenotypic analyses suggest a 
role for CD53 in immunodeficiency (Mollinedo et al., 1997) or various inflammatory disorders 
including arthritis, asthma and Sjögren’s syndrome (Bos et al., 2010; Khuder et al., 2015; Lee 
et al., 2013; Pedersen-Lane et al., 2007; Xu et al., 2015). Here, we analyse CD53 function using 
a reverse genetics approach. The data show a striking phenotype as CD53-deficient 
lymphocytes home poorly to lymph nodes, an effect associated with marked reductions in L-
selectin expression and stability on these cells. Thus, we demonstrate that CD53 is a key player 
in the regulation of lymphocyte recirculation.   
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RESULTS AND DISCUSSION 
 
The cellularity of Cd53-/- peripheral lymph nodes is reduced due to a striking defect in 
lymphocyte homing 
 
To investigate the function of the tetraspanin CD53, we first analysed the lymphoid organs of 
Cd53-/- mice. No difference in the gross appearance or mass of spleens was observed; however, 
Cd53-/- peripheral lymph nodes (pLN; inguinal and brachial) were smaller in appearance and 
weighed less than their wild-type (WT) counterparts (Fig. 1A). CD53 ablation had no 
significant effect on the cellularity of the bone marrow, thymus, blood, spleen, and mesenteric 
lymph nodes. However, pLN from Cd53-/- mice showed a striking defect in cellularity with a 
reduction of approximately 60% compared to WT (Fig. 1B). This was not a delay in 
development, since the cellularity in the spleens of WT and Cd53-/- mice was identical over 
time, whereas the pLN of Cd53-/- mice remained smaller even in 52-week-old mice (Fig. 1C). 
To further analyse the impaired cellularity of Cd53-/- pLN, cells from pLN and spleen were 
analysed by flow cytometry and lymphocytes enumerated. Dot plot analyses showed a slight 
increase in the frequency of T cells, and a striking reduction in the frequency of B cells in the 
pLN of Cd53-/- mice (Fig. 1D). Quantification of absolute B cell numbers confirmed this 
reduction,  (Fig. 1F). The number of pLN B cells in Cd53-/- mice was only ~14% of that in WT. 
For pLN T cells, quantification revealed a smaller, ~50% deficit, applying to both the CD4+ 
and CD8+ lineages. In parallel we observed a marginal, although significant, increase in the 
number of T cells in the spleen (Fig. 1E). 
 
Given the normal cellularity of the spleen and other lymphoid organs, and the documented 
roles of tetraspanins in regulating cell migration and leukocyte trafficking (Yeung et al., 2018), 
we reasoned that a defect in lymphocyte recirculation may underlie the phenotype of poor 
lymph node cellularity. We therefore evaluated whether CD53 ablation affected lymphocyte 
homing to lymph nodes. Firstly, to investigate whether CD53 ablation had an effect on lymph 
node architecture or on HEVs, homing assays were performed where WT splenocytes were 
labelled with CFSE and adoptively transferred into WT and Cd53-/- mice (Fig. 2A). Flow 
cytometric analysis was used to identify the relative frequency of adoptively-transferred 
splenocytes in each organ (Fig. 2B), and to distinguish B cells and T cells (data not shown). 
The data clearly show that whilst there was an impairment in the ability of adoptively-
transferred WT B and T cells to home to the spleens of Cd53-/- mice, homing to peripheral and 
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mesenteric lymph nodes was normal (Fig. 2C and 2D). Thus, the reduced cellularity of Cd53-
/-
 pLN is likely a phenotype intrinsic to Cd53-/- lymphocytes. Next, we investigated the homing 
capacity of Cd53-/- lymphocytes. WT and Cd53-/- B or T cells were purified, labelled with CFSE 
and co-injected into WT recipient mice together with an internal control of WT (B or T) cells 
differentially labelled with Cell Tracker 670 (Fig. 2E). Forty-eight hours later immune organs 
were harvested and homing analysed by flow cytometry (Fig. 2F and H). Quantification was 
calculated using a homing index (Arbones et al., 1994) where the ratio of CFSE+ test cells to 
Cell Tracker 670+ internal control cells in the initial injection mixture and also within each 
organ, was determined (Fig. 2G and I). For B cells, Cd53-deficiency resulted in a striking defect 
(Fig. 2F). Whilst Cd53-/- B cells were able to localise to blood normally, they preferentially 
localised to the spleen whilst homing to the pLN was almost completely abrogated (Fig. 2G). 
There was also a significant reduction of B cell homing to the mesenteric lymph nodes (25% 
of WT; Fig. 2G). A similar dysregulation in Cd53-/- T cell lymph node homing was observed 
although the phenotype was not as pronounced (Fig. 2H). Cd53-/- T cells also preferentially 
localised to the spleen, while homing to both the pLN and mLN was poor (Fig. 2I). In 
conclusion, CD53 ablation induces reduced cellularity in pLN due to a severe defect in 
lymphocyte homing, with the phenotype more pronounced in B cells than in T cells. 
 
 
CD53 ablation impairs expression of L-selectin on lymphocytes 
 
Given that CD53 ablation induces a defect in lymph node homing, we hypothesised that CD53 
might regulate the key lymph node homing receptor, L-selectin. We therefore analysed L-
selectin expression by flow cytometry and identified that the residual B cell (B220+) population 
found in Cd53-/- pLN had significantly reduced expression of L-selectin protein (Fig. 3A). 
Indeed, across spleen, pLN and mLN there was a major reduction in the surface expression of 
L-selectin on Cd53-/- B cells of up to two orders of magnitude (Fig. 3B). To investigate whether 
our findings extended to human cells, we generated human Cd53-/- B cell lines (BJAB) using 
CRISPR/Cas9 technology. We observed impaired cell surface L-selectin expression in two 
independent human Cd53-/- B cell lines, in accord with our mouse data (Fig. 3C). In 
comparison, the expression of L-selectin on Cd53-/- T cells revealed a small, but significant, 
reduction of L-selectin expression of 8 and 20% in splenic and pLN T cells respectively (Fig. 
3D-E). This diminution of L-selectin expression was exaggerated in T cells from aged mice 
where there was an approximate 60% reduction of L-selectin expression (Fig. 3F).  
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To investigate the mechanism by which CD53 regulates L-selectin we first analysed mRNA 
expression in lymphocytes and could detect no reduction in L-selectin mRNA expression 
associated with CD53 ablation in both resting and activated cells (Figure S1). We next 
hypothesised that CD53 might have a role in L-selectin trafficking and therefore analysed L-
selectin expression in permeabilised lymphocytes. Whilst we could detect a subtle increase in 
intracellular L-selectin expression in CD53-/- T cells, there was no evidence of an intracellular 
accumulation of L-selectin in CD53-/- B cells, arguing against a role for CD53 in trafficking L-
selectin to the cell surface. (Figure S2). L-selectin is cleaved from the surface of lymphocytes 
by metalloproteases. In activated lymphocytes, the predominant metalloprotease that drives 
shedding is ADAM17, whereas the metalloprotease responsible for the constitutive shedding 
observed in unactivated lymphocytes has not been identified (Mohammed et al., 2019).  There 
is growing evidence that tetraspanins can regulate this enzyme family. For example, the 
TspanC8 subgroup of tetraspanins molecularly interact with and regulate the activity of 
ADAM10 (Matthews et al., 2017). We therefore investigated whether CD53 regulates L-
selectin expression via effects on metalloproteases. We first examined L-selectin expression 
on unactivated WT and Cd53-/- B cells incubated at 37oC in the presence of the broad-spectrum 
matrix metalloprotease inhibitor GM6001. Incubation of WT B cells at 37oC induced a 
spontaneous reduction in L-selectin expression, which was completely inhibited by GM6001 
(Fig 3H). L-selectin expression on Cd53-/- B cells was much lower than on WT cells, and while 
incubation of Cd53-/- B cells with GM6001 (Fig. 3G and H) increased L-selectin expression 
more than 3-fold,  it could not restore expression to WT levels. This suggests that the reduced 
L-selectin expression in Cd53-/- B cells may be only partially accounted for by 
metalloproteinase activity.  Incubation of WT T cells at 37oC also induced a spontaneous 
reduction in L-selectin expression, and this reduction was significantly exaggerated in Cd53-/- 
T cells (Fig. 3I and J). In marked contrast to B cells, the reduced levels of L-selectin on CD53-
/-
 T cells were substantially restored up to ~ 80% of WT levels by GM6001. This finding 
suggests that the lower levels of L-selectin in CD53-/- T cells are largely due to spontaneous 
shedding. To study the impact of CD53 on ADAM-17-dependent L-selectin shedding in T 
cells, we used PMA activation and observed that L-selectin shedding from Cd53-/- T cells was 
significantly accelerated (Fig. 3K and L), with an increase in soluble L-selectin levels observed 
in the supernatant of Cd53-/- as compared to WT cells (Fig. 3M). Whilst GM6001 and another 
metalloprotease inhibitor that can inhibit ADAM17 (chemical inhibitor TAPI-1) were able to 
largely prevent shedding in WT T cells and maintain L-selectin at ~70% of unstimulated levels, 
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these inhibitors were all less effective in preventing shedding in Cd53-/- T cells, but did partially 
maintain L-selectin expression at ~25% of unstimulated levels. Similarly, the ADAM-17 
blocking mAb A9 (Kwok et al., 2014) was also less effective in blocking PMA-induced L-
selectin shedding in CD53-/- T cells. The ADAM-10 specific  inhibitor GI254023X failed to 
prevent shedding from Cd53-/- T cells (Fig. 3N), demonstrating that ADAM10 did not substitute 
for ADAM-17 in PMA-activated T cells as shown here and by others (Mohammed et al., 2019). 
 
In summary, treatment with metalloprotease inhibitors: increases the expression of L-selectin 
on Cd53-/- B cells (Fig. 5G-H), prevents the instability of L-selectin on Cd53-/- T cells (Figs 5I-
J, and partially restores L-selectin expression in PMA-treated Cd53-/- T cells (Figs. 5K and N). 
Taken with the exaggerated accumulation of L-selectin in the supernatant of PMA-activated 
Cd53-/- T cells (Fig 5M), the data supports a role for CD53 in inhibiting metalloprotease 
mediated shedding of L-selectin from the lymphocyte surface.  Analyses of ADAM17-deficient 
cells and mice indicate that there are additional mechanisms of L-selectin shedding that are 
independent of ADAM17 (Le Gall et al., 2009; Walcheck et al., 2003; Wang et al., 2010). 
Given that metalloprotease inhibitors, or a blocking antibody targeting ADAM17, diminished 
but did not abrogate the excessive shedding of L-selectin induced by PMA stimulation in Cd53-
/- T cells, our data indicate that CD53 also inhibits ADAM17-independent mechanisms, some 
of which may be metalloprotease independent. Taken together, we conclude that CD53 is 
required to stabilise L-selectin expression at the lymphocyte surface and further studies will be 
required to identify the additional metalloproteinase(s) or mechanisms responsible.  
 
Cd53-/- B cells express very low levels of L-selectin, and consequently are unable to home to 
peripheral lymph nodes. By contrast, L-selectin expression in Cd53-/- T cells is only marginally 
reduced (Fig. 3) but is unstable, as shown by the relatively poor expression of L-selectin on T 
cells from aged Cd53-/- mice (Fig. 3F), and the spontaneous loss of L-selectin surface 
expression induced by incubation of Cd53-/- T cells at 37oC (Fig. 3I and J). This L-selectin 
instability likely explains the impairment of Cd53-/- T cell homing to peripheral lymph nodes, 
although we cannot rule out other mechanisms such as a defect in signal transduction. In line 
with this, we have recently shown that CD53 can directly interact with PKC and is required for 
PKC activation in B cells (Zuidscherwoude et al., 2017), suggesting that CD53 interacts with  
PKC and L-selectin in the same molecular complex (Kilian et al., 2004). The difference in the 
biology of CD53 ablation on B and T cells likely reflects the ratio of CD53:L-selectin 
expression on the two cell types. CD53 is expressed at higher levels on B cells than on T cells 
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(Tomlinson et al., 1995), whereas T cells express approximately 50% more L-selectin than do 
B cells (Gauguet et al., 2004). Thus, on B cells there is relatively more CD53 available to 
inhibit the shedding of lower levels of L-selectin (and vice versa). Alternatively, there may be 
another tetraspanin that compensates for CD53 on T cells but is not expressed in B cells. One 
candidate is CD9, as in vitro studies have shown that it can inhibit ADAM17-mediated 
shedding of another substrate, TNF (Gutierrez-Lopez et al., 2011), and it is strongly expressed 
on T cells but not on most B cells. However, we think this unlikely, lymph node cellularity in 
Cd9-/- mice is normal (Iwasaki et al., 2013), and CD53 ablation does not significantly affect 
CD9 expression in either Cd53-/- T cells or hCd53-/- BJAB cells (Figure S3).  
 
Defective lymphocyte homing delays adaptive immune responses when antigen is 
delivered to lymph nodes 
 
To examine whether the impairment of lymphocyte recirculation in Cd53-/- mice had an effect 
on immunity, mice were first challenged with classical model antigens (namely the Type I T-
independent antigen NP-LPS, the type II T-independent antigen NP-FICOLL, and the classical 
T-dependent antigen NP-KLH) to induce humoral responses. Antibody responses of Cd53-/- 
mice were largely normal to all antigens administered systemically (i.p., Fig. 4A, C and E). 
Similarly, responses to intradermal NP-LPS were also normal (Fig. 4D). Collectively, these 
data indicate that CD53 ablation does not significantly affect the germinal centre reaction, 
antigen presentation, T cell help, or the ability of B cells to proliferate and generate plasma 
cells.  However, when NP-KLH was delivered to lymph nodes via intradermal injection, Cd53-
/-
 antibody responses were significantly delayed (Fig. 4F). Similarly, with regard to T cell 
responses, the clinical responses of Cd53-/- mice in experimental autoimmune 
encephalomyelitis (EAE), a T cell-dependent model of autoimmunity initiated by subcutaneous 
immunization with MOG peptide, were also delayed (Fig. 4G). We conclude, that when antigen 
is delivered to the lymph nodes of Cd53-/- mice, adaptive immune responses are delayed or 
impaired. This pattern of normal responses to systemically-administered antigen versus 
delayed or impaired immunity when antigen is delivered to pLN via the subcutaneous and 
intradermal routes is strikingly similar to that reported for L-selectin knockout mice (Catalina 
et al., 1996; Steeber et al., 1996). This illustrates the importance of lymphocyte recirculation 
in immunity; presumably, the poor cellularity of lymphocytes, particularly B cells, in the lymph 
node delays immune responses. The one exception here was the exaggerated immune responses 
of Cd53-/- mice to NP-FICOLL when administered intradermally (Fig. 4B). It is difficult to 
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explain this result although this was also observed in L-selectin deficient mice (Steeber et al., 
1996). T-independent type II antigen responses arise in the marginal zone of the spleen where 
marginal zone B cells, B1 cells and splenic macrophages are all thought to play a critical role 
(Vinuesa and Chang, 2013). The numbers of these cell populations are normal in Cd53-/- mice 
and we can only speculate either that a deficiency in the CD53/L-selectin axis induces subtle 
changes in trafficking or localisation in these populations or that L-selectin expressed in these 
populations has a hitherto undiscovered function in negatively regulating type II T-independent 
responses.  
 
 
Concluding remarks 
These analyses identify an indispensable role for CD53 in maintaining lymph node cellularity 
(Fig. 1).  A very recent analyses of Cd53-/- mice, attributed the poor lymph node cellularity to 
defects in B cell development and showed evidence that CD53 is required for optimal IL-7R 
signalling (Greenberg et al., 2020). Here we identify another mechanism: CD53 is required for 
lymphocyte homing to lymph nodes (Fig. 2). The central role of L-selectin in lymph node 
homing is well-established. However, the molecular mechanisms underlying L-selectin 
stabilisation at the plasma membrane are less well understood. This paper demonstrates that L-
selectin on lymphocytes is tightly controlled by the leukocyte-specific tetraspanin CD53 and 
that CD53 mediates this effect by inhibiting L-selectin shedding (Fig. 3). Consequently, CD53 
is required for efficient and timely immune responses (Fig. 4). 
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Methods 
 
Mice 
 
The generation of Cd53-/- mice has been recently described (Zuidscherwoude et al., 2017). Both 
Cd53-/- and C57BL/6J (wild-type, WT) mice were bred at the Monash Animal Research 
Platform (MARP), or Animal Research Laboratories (ARL) at Monash University (Clayton 
campus, Australia) or the Precinct Animal Centre (PAC) at the Alfred Research Alliance 
(formerly the Alfred Medical and Research Education Precinct (AMREP)) Melbourne, under 
specific-pathogen free conditions. All mice used for experimentation were between 4-12 weeks 
of age (or as indicated in text) and C57BL/6J age- and sex-matched mice were used as controls. 
The AMREP AS Animal Ethics Committee approved all experiments.  
 
Lymphoid organ single cell suspensions 
Lymphoid organs (including spleen, thymus, peripheral (inguinal and brachial) and mesenteric 
lymph nodes, were aseptically removed from WT and Cd53-/- mice. Blood (500 L, collected 
by cardiac puncture) was placed into an equal volume of Alsever’s solution to prevent 
coagulation. Single cell suspensions were prepared by disruption of organs in appropriate 
buffer. Bone marrow was flushed from the femur and tibia of WT and Cd53-/- mice using 25G 
needles. Erythrocytes in spleens, bone marrow and blood were lysed in ice-cold ACK lysis 
buffer. All suspensions were filtered through 70 m strainers to remove cellular debris and 
washed. Viable cells were enumerated on a haemocytometer using trypan blue exclusion. 
 
Flow cytometry 
Cells were labelled with antibodies against a range of surface markers conjugated to a range of 
fluorochromes as follows: anti-B220 FITC* or APC Cy7 (RA3-6B2), anti-CD3 FITC, and 
Cy5* (KT31.1), anti-CD4 Pacific Blue (RM4-5), anti-CD8 PE or APC Cy7 (53-6.7), anti-
CD19 PE or eFluor450 (1D3), anti-CD53* (OX-79) and anti-L-selectin PE or PE Cy7 (MEL-
14). Antibodies with an asterisk were purified and conjugated in house, all others were 
purchased from BD Pharmingen (San Diego, CA) or eBioscience (CA, USA).  Antibodies were 
diluted to the appropriate titrated concentration in appropriate buffer, and cells stained on ice 
for 30 min. Cells were washed and resuspended in buffer containing 0.2% v/v propidium iodide 
prior to acquisition on a BD FACSCalibur, LSR II or LSRFortessa (BD Biosciences). Cells 
were analysed using FlowJo Software (TreeStar Inc., OR, USA) following exclusion of 
doublets and propidium iodide-positive cells. For assessment of surface and intracellular L-
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selectin, non-permeabilised lymph node cells were first stained for surface L-selectin using PE-
conjugated anti-L-selectin (clone = MEL-14) at a concentration (8 g/ml) determined in pilot 
experiments to minimize any further staining achieved by subsequent exposure to anti-L-
selectin-FITC (data not shown). Cells were subsequently washed, fixed/permeabilized (BD 
Cytofix/Cytoperm, BD Biosciences Pharmingen) and stained for intracellular L-selectin using 
FITC-conjugated anti-L-selectin (5 g/ml).  Surface and intracellular L-selectin levels were 
determined via flow cytometric analysis, identifying T cells as TCR beta chain+ cells (clone = 
H57-597, conjugated to APC), and B cells as CD19+ cells (clone = 1D3, conjugated to BV711). 
 
 
 
B and T cell isolation 
B cells were isolated by negative selection from the spleens of WT and Cd53-/- mice using the 
Dynabeads Mouse CD43 (Untouched B cells) kit (Life Technologies, CA, USA) according to 
the manufacturer’s instructions.  Negative selection by magnetic bead depletion was used for 
T cell isolation as previously described (Sheng et al., 2009).  
 
Homing Assays  
WT splenocyte homing assay. Single cell suspensions of WT spleens were prepared as 
described above. Splenocytes were labeled with 0.5 μM CFSE (10 mins, 37C; Life 
Technologies, CA, USA). 3x107 splenocytes in 100 μL PBS were injected i.v. into WT and 
Cd53-/- mice. Spleens, peripheral (inguinal and brachial) LNs, mesenteric LNs and blood were 
harvested 48 h later and single cell suspensions analysed by flow cytometry for the presence 
of CFSE+ splenocytes, including CFSE+ CD19+ B cells and CFSE+ CD3+ T cells. Absolute 
CFSE+ cell number in each organ was calculated based on frequencies of CFSE+ cells and 
organ cell counts.  
B and T cell homing assays.  B and T cells from WT and Cd53-/-
 
mice were isolated and labelled 
with CFSE as above. WT cells were also labelled with 1 μM Cell Proliferation Dye eFluor670 
(referred to in this article as Cell Tracker 670; 10 min, 37C; eBioscience, CA, USA) for use 
as an internal control. 107 WT or Cd53-/- CFSE-labelled B or T cells were mixed in equal 
numbers with Cell Tracker 670-labelled WT B or T cells and injected i.v. into WT mice in 100 
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μL PBS. The injected cell mixture was analysed by flow cytometry to determine the ratio of 
fluorescently-labelled cells in the starting preparation. Lymphoid organs were harvested after 
48 h and analysed by flow cytometry for fluorescently-labelled CD3+ T cells or CD19+ B cells. 
Homing indices were calculated according to the following formula:  
Homing index = (Sample:Internal control)organ / (Sample:Internal control)injected  (Arbones et 
al., 1994). 
 
 
Gene expression by real-time quantitative PCR (qPCR) 
Purified B and T cells were activated for 18 h with 10 g/mL of LPS (from E. coli K12; 
InvivoGen, CA, USA) or 10 g/mL immobilised anti-CD3 plus 1 g/mL soluble anti-CD28, 
respectively. Activated cells were analysed by flow cytometry for the upregulation of CD69 
and/or CD25. RNA was isolated from purified B and T cells (naïve or activated) using the spin 
purification protocol from the SV Total RNA Isolation System (Promega, WI, USA) and 
converted to cDNA through the use of an RNA to cDNA kit according to manufacturer 
instructions (Life Technologies, CA, USA). Levels of mouse L-selectin and 18S mRNA were 
measured using predesigned Taqman® Gene Expression Assays (Catalog Mm_0041291_m1 
and Mm_03928990_g1; Life Technologies, CA, USA). qPCR was performed according to 
manufacturer instructions in an ABI Prism® 7900HT Sequence Detection System (Life 
Technologies).   
 
L-selectin shedding assays  
2-2.5x106 cells/well of purified wild-type and Cd53-/- mouse T lymphocytes were activated at 
37°C with 50 ng/mL (80 nM) PMA in 0.5% BSA/RPMI at designated time points (2.5, 5, 15, 
and 30 min) to induce L-selectin shedding from the cell surface. When required, cells were 
pre-incubated at 37°C with inhibitors for 10 min prior to the addition of PMA. A broad 
spectrum metalloprotease inhibitor GM6001 (Tocris Bioscience, Bristol, UK), TAPI-1 (an 
inhibitor of ADAM17, Tocris Bioscience), ADAM17-specific inhibitory antibody A9(B8) 
(Kwok et al., 2014) and GI254023X (a potent inhibitor of ADAM10, Tocris Bioscience) were 
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added at final concentrations of 100 μM, 20 μM, 200 nM or 5 μM respectively. An unstimulated 
control (no PMA) was included, where 0.5% BSA/RPMI was added to cells instead. All 
reactions were stopped by placing wells on ice. Cells were then centrifuged at 1,800 rpm for 5 
min at 4°C. The supernatant was harvested for ELISA experiments, and cells were resuspended 
in FACS buffer. 5x105 cells were stained with anti-CD3 FITC, and anti-L-selectin PE. Levels 
of L-selectin shedding were determined by flow cytometry on the FACSCalibur (BD 
Biosciences) or the LSRFortessa (BD Biosciences)
. 
A sandwich ELISA was used to determine 
soluble L-selectin levels in supernatants from activated T and B cells. Wells were coated with 
anti-mouse L-selectin (clone 95226; R&D Systems, MN, USA) and L-selectin detected by 
biotinylated anti-mouse L-selectin (clone 95218; R&D Systems, MN, USA). Recombinant 
mouse L-selectin/CD62L Fc Chimera was used as a standard in all assays (R&D Systems, MN, 
USA). Streptavidin-HRP, TMB (Life Technologies, CA, USA) and 1M HCl were used for 
detection. OD was determined at 450 nm (Multiskan Go plate reader, ThermoFisher Scientific). 
For long-term assays to measure spontaneous L-selectin shedding without PMA activation, 
2x106 cells were incubated as above and for 1, 2 or 3 h. Cells were harvested and stained with 
antibodies to L-selectin, CD3 or B220 as required, prior to acquisition on a flow cytometer.  
 
Analysis of human Cd53-/- B cells 
 
Monoclonal and polyclonal Cd53-deficient human BJAB cells were generated by CRISPR-
Cas9 technology as previously described (Zuidscherwoude et al., 2017). DNA electroporation 
of WT and CD53-deficient cells was performed with the Neon® Transfection System 
MPK5000 (Thermo Fisher Scientific, MA, USA). Per transfection, 4.8 × 106 cells were washed 
in PBS and resuspended in 120 L resuspension buffer R and mixed with 0.5 g pmaxGFP™ 
(Cell Line Optimization Solution Box; Lonza, Basel, CH) and 1.5 g L-selectin DNA. A 
volume of 100 L was transferred to a Neon® Electroporation Tube in a 100 L Neon® Tip 
(Neon® Transfection System 100 µL Kit; MPK10096, Invitrogen). A single electroporation 
pulse of 1350V for 40 ms was given. After transfection, cell suspensions were resuspended in 
3 mL RPMI without antibiotics and cultured overnight at 37oC and 5% CO2. 
 
Transfected cells were kept at optimal densities for 48 h. Three groups of 2×105 cells per 
transfected and untransfected controls were washed in PBS and resuspended in either PBA (1x 
PBS, 1% BSA, 0.05% NaN3), 1g/mL mouse IgG1 isotype (clone MOPC-21; BioLegend, SD, 
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USA) or 1 g/mL mouse anti-human anti-L-selectin (clone DREG56; Novus, Manchester, UK) 
and incubated on ice for 30 min. Cells were washed in PBS and resuspended in either PBA 
(PBS, or goat anti-mouse IgG1 Alexa Fluor® 647 (Invitrogen, MA, USA) and incubated in the 
dark on ice for 30 min. Cells were then washed in PBS and resuspended in 150 L PBA and 
analyzed on MACSQuant® Analyzer 10 flow cytometer (Milteny Biotec, Bergisch Gladbach, 
DE). 
 
 
Induction and measurement of immune responses 
Mice were immunised intraperitoneally (i.p.) or intradermally (i.d.) at the base of the tail with 
100 μg NP(25-28)-KLH (Biosearch Technologies, Novato, CA) precipitated in alum (10% 
w/v) as an adjuvant (T-cell dependent responses) or with 50 μg NP(0.6)-LPS or NP(40)-
AECM-FICOLL in PBS (Biosearch Technologies, Novato, CA) (T-cell independent 
responses). A pre-bleed (submandibular) was taken before immunisation and submandibular 
bleeds were taken weekly from immunised mice. ELISAs to determine isotype specific 
antibody responses against NP were performed as previously described (van Spriel et al., 
2009).  
To measure T cell responses, mice were immunised intradermally at the base of the tail with 
5x106 γ-irradiated B16OVA cells in 100 μL of mPBS. Antigen-specific T cell responses were 
determined by ELISPOT 14 d following immunisation as previously described (Gartlan et al., 
2013).  
EAE was induced by MOG35-55 immunisation following a standard protocol (Chan et al., 
1997). Briefly, mice were immunised subcutaneously in each flank with 100 μg MOG35-55 
(GL Biochem, Shanghai, China) emulsified in CFA supplemented with 4 mg/mL of 
Mycobacterium tuberculosis H37Ra (DICO laboratories, USA) and also injected on the same 
day i.p. with 350 ng/mouse Pertussis toxin (List Biological laboratories, USA) in PBS. Forty-
eight hours later mice were re-injected with 350 ng/mouse Pertussis toxin i.p. Mice were 
monitored daily for weight loss and clinical signs of EAE. Clinical scores were assigned 
according to the following: 0, no disease; 1, tail weakness; 2, tail paralysis and hind limb 
weakness; 3, hind limb paralysis; 4, hind and forelimb paralysis; 5 death. For ethical reasons 
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mice were culled when a clinical score of 3 was reached.  
Statistical analysis  
The student’s two tailed t-test, or Mann-Whitney test, or 2-way ANOVA (for EAE) was used 
to for statistical comparisons between data sets. GraphPad Prism 6 software (CA, USA) was 
used for statistical analysis.  
  
 
Figure Legends 
 
Figure 1. CD53 ablation reduces the cellularity of peripheral lymph nodes. Lymphoid 
organs from 10-week-old WT and Cd53-/- mice were harvested and analysed. (A) 
Representative images and mass of WT and Cd53-/- spleens and peripheral lymph nodes (pLN). 
(B) Total cell numbers of lymphoid organs (BM, bone marrow; Thymus; Blood; Spleen; 
mesenteric lymph nodes (mLN); and pLN). (C) Total cell number of spleens and pLN as 
determined at timepoints from 4-52 weeks. (D) Flow cytometry analyses of spleen and pLN 
identifying B (B220+) and T (CD3+) cell, and CD4 + and CD8+ T cell populations. (E-F) 
Quantification of (E) T cell and (F) B cell populations in spleen, and pLN. Data are represented 
as mean  SEM, n=6-17 mice per group pooled from 2-5 independent experiments, * p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
 
 
Figure 2.  CD53 is required for efficient lymphocyte homing to lymph nodes. (A-D) WT 
splenocytes were labelled with CFSE and injected i.v. into WT or Cd53-/- recipient mice. Forty-
eight hours later lymphoid organs were harvested and analysed for CFSE+ cells using flow 
cytometry. (A) Schematic, illustrating experimental design. (B) Representative flow cytometry 
illustrating the identification of transferred CFSE+ cells in the spleens and pLN of recipient 
mice. (C and D) Enumeration of CD19+CFSE+ adoptively transferred B cells (C) and 
CD3+CFSE+ adoptively transferred T cells (D) in the lymphoid organs of recipient mice. Data 
are from 8 mice per group pooled from 2 independent experiments.  (E-I) WT and Cd53-/- B or 
T cells were purified, CFSE-labelled and co-injected i.v. into WT recipient mice together with 
an internal control of WT (B or T) cells differentially labelled with Cell Tracker 670. (E) 
Schematic, illustrating experimental design. (F and H) Representative flow cytometry 
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comparing the homing of WT-Cell tracker 670+, WT-CFSE+, and Cd53-/-CFSE+ CD19+ B cells 
(F) and CD3+ T cells (H) to peripheral lymph nodes.  (G and I) Homing indices of transferred 
B cells (G) and T cells (I) to each organ. Data are represented as mean  SEM, 8 mice per 
group pooled from 2 independent experiments, * p ≤ 0.05, *** p ≤ 0.001.  
 
Figure 3. CD53 stabilises L-selectin expression on the lymphocyte surface. (A) 
Representative flow cytometry histograms (splenic B cells)  and quantification of L-selectin 
protein expression (B; Mean fluorescent intensity, MFI) on B220+ WT and Cd53-/- B cells 
harvested from spleen, peripheral lymph nodes (pLN) and mesenteric lymph nodes (mLN). 
Data are represented as mean + SEM, 3 mice per group, representative of 3 independent 
experiments. (C) Expression of WT human L-selectin on WT and hCd53-/- human BJAB cells.  
(D) Representative flow cytometry (splenic T cells) and quantification (E, MFI) of L-selectin 
expression on CD3+ WT and Cd53-/- T cells harvested from spleen and pLNs harvested from 
10-week-old mice. Data are represented as mean + SEM, 10 mice per group pooled from 2 
independent experiments. (F) Quantification of L-selectin expression (MFI) on CD3+ T cells 
harvested from aged (52-week-old) WT and Cd53-/- mice. Data are represented as mean  SEM, 
n=6 mice per group representative of 2 independent experiments. (G-J) WT and Cd53-/- 
splenocytes were cultured at 37oC with or without the broad metalloprotease inhibitor GM6001 
(GM; 100M). Flow cytometry was used to distinguish B (B220+) and T (CD3+) cells and 
monitor L-selectin expression. (G and I) Representative flow cytometry histograms displaying 
L-selectin expression on B cells (G) and T cells (I) after 2 h at 37oC. (H and J) The kinetics of 
L-selectin expression on cultured B (H) and T (J) cells relative to cells held at 4oC. (K-N) 
Purified WT and Cd53-/- T cells were stimulated with PMA (50 ng/mL) to induce shedding in 
the presence or absence of metalloprotease inhibitors. (K) Representative histograms 
illustrating L-selectin expression in unstimulated (unstim), PMA stimulated (5’), and PMA 
stimulated in the presence of the metalloprotease inhibitor GM6001 (PMA 5’ + GM). (L) The 
kinetics of L-selectin surface expression (relative to unstimulated cells) and (M) amount of 
soluble L-selectin shed into supernatants of WT and Cd53-/- T cells stimulated with PMA. (N) 
The percentage of L-selectin expression (relative to unstimulated cells) remaining after 15’ 
PMA stimulation in the presence or absence of the metalloprotease inhibitors GM6001 (100 M, GM), GI254023X (20 M GI), TAPI-1 (200 M) and A9 (5 M). Data are represented as 
mean  SEM, n=6-7 mice per group pooled from 3 independent experiments, * p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.   
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Figure 4. Adaptive immune responses in Cd53-/- mice are delayed when antigen is 
delivered to lymph nodes. (A-F) WT and Cd53-/- mice were immunised i.p. (IP; A, C and E) 
or intradermally (ID; B, D and F) with (A-B) 50 g of NP-FICOLL, (C-D) 50 g of NP-LPS 
or (E-F) 50 g of NP-KLH. NP-specific antibody responses were determined by ELISA for 
IgM, IgG1, IgG2b and IgG3. Data are represented as mean  SEM. 9-17 mice per group pooled 
from 2 independent experiments. (G) EAE was induced in WT and Cd53-/- mice where mice 
were immunised subcutaneously with MOG peptide. Disease progression was measured daily 
and expressed as a clinical score as mean  SEM. 10 mice per group from 2 independent 
experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
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